Outcome and late effects of patients treated for childhood vaginal malignant germ cell tumors

Robin Coppin (1, 2) , Hélène Martelli (2) , Cyrus Chargari (2, 1) , Hélène Sudour-Bonnange (3) , Daniel H. Orbach (4) , Cécile Vérité (5) , Marlène Pasquet (6) , Laure Saumet (7) , Christophe Piguet (8) , Catherine Patte (2, 1) , Florent Guérin (2) , Cecile F.Aure Faure-Conter (9) , Brice C. Fresneau (10)

1 IGR - Institut Gustave Roussy
2 Université Paris-Saclay
3 UNICANCER/Lille - Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille]
4 Institut Curie [Paris]
5 CHU Bordeaux
6 Département Oncologie médicale digestive [CHU Toulouse]
7 CHU Montpellier
8 CHU Limoges
9 IHOPe - Institut d'hématologie et d'oncologie pédiatrique [CHU - HCL]
10 CESP - Centre de recherche en épidémiologie et santé des populations

Purpose: Vaginal malignant germ cell tumors (MGCT) are rare, occurring in children less than 2 years old and raise the question of the optimal local treatment. Methods: We included children treated for vaginal MGCT according to the French TGM-95/2013 regimen. Patients were classified as standard risk (SR: localized disease and alpha-fetoprotein (AFP) < 10,000 ng/mL) or high risk (HiR: metastatic and/or AFP > 10,000 ng/mL) and were treated, respectively, with three to five VBP (vinblastine–bleomycin–cisplatin) or four to six VIP (etoposide–ifosfamide–cisplatin), followed by conservative surgery and/or brachytherapy in case of post-chemotherapy residuum. Results: Fourteen patients were included (median age = 12 months), of which six (43%) were classified as HiR. AFP levels were normalized after first-line chemotherapy in all cases but one. A vaginal post-chemotherapy residuum (median size = 8 mm, range: 1–24 mm) was observed in 13/14 patients, treated by complete resection in seven of 13 (viable cells in three of seven), incomplete resection in four of 13 (viable cells in two of four), with adjuvant brachytherapy in two of 13, and exclusive brachytherapy in two of 13 (viable cells in one of six). Among the six patients with viable disease, four patients received adjuvant chemotherapy. One patient (SR) experienced immediate postoperative relapse despite presenting no viable residual cells and was treated with four VIP cycles and brachytherapy. At last follow-up (median = 4.6 years, range: 0.5–16), all patients were alive in complete remission. Five patients suffered from vaginal sequelae with synechiae and/or stenosis (of whom four had undergone brachytherapy). Conclusion: Childhood vaginal MGCTs show a highly favorable prognosis with risk-adapted chemotherapy and local treatment of post-chemotherapy residuum (preferably by conservative surgery with partial vaginectomy). Brachytherapy could be an alternative when conservative surgery is not deemed possible or in cases of incomplete resection with residual viable cells.

Mots clés: alpha-fetoprotein; brachytherapy; children; germ cell tumors; surgery; vaginal tumors

Domaines: Sciences du Vivant [q-bio]

Robin Coppin, Hélène Martelli, Cyrus Chargari, Hélène Sudour-Bonnange, Daniel H. Orbach, et al.. Outcome and late effects of patients treated for childhood vaginal malignant germ cell tumors. Pediatric Blood and Cancer, 2023, 70 (12), ⟨10.1002/pbc.30697⟩. ⟨hal-04271278⟩